Look for Drugs and Conditions

Buserelin Acetate

Buserelin Acetate

It is a synthetic peptide analog of the natural gonadotropin releasing hormone (GmRH/LHRH) with enhanced biological activity. After repeated administration of buserelin, the secretion of gonadotrophin release and gonadal steroids is significantly inhibited. The pharmacological effect is attributable to the down-regulation of pituitary LHRH receptors.

Indications

Subcutaneous injection, The palliative Treatment (initial and maintenance treatment) of patients with hormone-dependent advanced carcinoma of the prostate gland (stage D). Nasal solution; The palliative Treatment (maintenance treatment) of patients with hormone-dependent advanced carcinoma of the prostate gland (stage D). The treatment of endometriosis in patients who do not require surgery as primary therapy. The duration of Treatment is usually six months and should not exceed nine months.


Dosage

Patients with Prostatic Cancer Initial treatment: For the first seven days of treatment give buserelin 500mcg (0.5ml) every 8 hours by subcutaneous injection. For patient comfort, vary the injection site. Maintenance treatment: Depending upon patient preference, or Physician recommendation, maintenance treatment may be by daily subcutaneous injection or by intranasal administration three times daily. During maintenance dosing by the subcutaneous injection route, the buserelin dose is 200mc


Contra-Indications

Hypersensitivity, Prostate cancer who do not present with hormone dependent carcinoma and in patients who have undergone orchiectomy, undiagnosed vaginal bleeding.


Special Precautions

Paediatrics: data not sufficient. Pregnancy: contraindicated Lactation: contraindicated Elderly: data not sufficient


Side Effects

Hot flushes, loss of libido, impotence, nasal irritation (nasal solution) and headache (nasal solution)


Drug Interactions

Antiarrythmic drugs, opoids, macrolide antibiotics


Other Brands With Same Generic
Brand Name Manufactured by
BUSARDIN INTAS PHARMACEUTICALS LTD.
Ad 5